跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

B1542

Sigma-Aldrich

[Lys-des-Arg9]-Bradykinin

≥95% (HPLC)

别名:

des-Arg10-Kallidin

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C50H73N13O11
CAS号:
71800-36-7
分子量:
1032.20
MDL號碼:
MFCD00079826
分類程式碼代碼:
12352209
PubChem物質ID:
329773191
NACRES:
NA.32

品質等級

200

化驗

≥95% (HPLC)

形狀

powder

UniProt登錄號

P01042

儲存溫度

−20°C

SMILES 字串

NCCCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](Cc5ccccc5)C(O)=O

InChI

1S/C50H73N13O11/c51-22-8-7-17-33(52)42(66)58-34(18-9-23-55-50(53)54)46(70)63-26-12-21-40(63)48(72)62-25-10-19-38(62)44(68)56-29-41(65)57-35(27-31-13-3-1-4-14-31)43(67)60-37(30-64)47(71)61-24-11-20-39(61)45(69)59-36(49(73)74)28-32-15-5-2-6-16-32/h1-6,13-16,33-40,64H,7-12,17-30,51-52H2,(H,56,68)(H,57,65)(H,58,66)(H,59,69)(H,60,67)(H,73,74)(H4,53,54,55)/t33-,34-,35-,36-,37-,38-,39-,40-/m0/s1

InChI 密鑰

AILVBOHFGXNHCC-TZPCGENMSA-N

基因資訊

human ... KNG1 (includes EG:3827)

Amino Acid Sequence

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe

應用

[Lys-des-Arg9]-Bradykinin has been used as a B1R agonist to investigate the role of B1R in diabetes-induced secondary hemorrhage.

生化／生理作用

[Des-Arg10]-kallidin or [Lys-des-Arg9]-Bradykinin is a bradykinin B1 receptor agonist. It strongly upregulates the B1 receptor and is blocked by a specific protein kinase C inhibitor. The upregulation is correlated with the induction of transcription nuclear factor κB (NF-κB). Elevation of Lys-des[Arg9]–bradykinin because of airway inflammation in asthma patients is known to modify the immune responses. It affects the migration and production of interleukin-12 in monocyte-derived dendritic cells.

其他說明

Lyophilized from 0.1% TFA in H2O

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Edson L Santos et al.
International immunopharmacology, 8(2), 282-288 (2008-01-10)
In the kallikrein-kinin and renin-angiotensin systems the main receptors, B1 and B2 (kinin receptors) and AT1 and AT2 (angiotensin receptors) respectively, are seven-transmembrane domain G-protein-coupled receptors. Considering that the B1 agonists Des-Arg9-BK (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe), Lys-desArg9-BK or Des-Arg10-KD (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe) and the AT1
J A Santiago et al.
The American journal of physiology, 269(6 Pt 2), H2057-H2064 (1995-12-01)
Responses to kallidin, des-Arg9-bradykinin (DABK), and des-Arg10-kallidin (DAK) were investigated in the hindlimb vascular bed of the cat under constant-flow conditions. Injections of kallidin, DABK, and DAK into the hindlimb perfusion circuit produced dose-dependent vasodilator responses in the hindlimb vascular
Shingo Sugahara et al.
European journal of pharmacology, 476(3), 229-237 (2003-09-13)
We evaluated roles of kinins in allergen-induced nasal blockage and sneezing, and development of nasal hyperresponsiveness to leukotriene D4 in a Japanese cedar pollen-induced allergic rhinitis model of guinea pigs. Sensitised guinea pigs were repeatedly challenged by pollen inhalation once
Richard W Ransom et al.
European journal of pharmacology, 499(1-2), 77-84 (2004-09-15)
Compound A (N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-2-[(2R)-1-(2-napthylsulfonyl)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl]acetamide) is a member of a new class of aryl sulfonamide dihydroquinoxalinone bradykinin B1 receptor antagonists that should be useful pharmacological tools. Here we report on some of the pharmacological properties of compound A as well as the
Jon E Hawkinson et al.
The Journal of pharmacology and experimental therapeutics, 322(2), 619-630 (2007-05-02)
The bradykinin B(1) receptor plays a critical role in chronic pain and inflammation, although efforts to demonstrate efficacy of receptor antagonists have been hampered by species-dependent potency differences, metabolic instability, and low oral exposure of current agents. The pharmacology, pharmacokinetics
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门